Centenial Surgical Suture posts a ₹2.2 cr annual loss on flat revenue

Tipsheet Editorial — Sat, 30 May 2026 21:35:11 GMT

A ₹2.31 crore fourth-quarter loss wiped out the small profit earned through the first nine months. Full-year revenue held flat at ₹53.84 crore.

What’s new

Full-year revenue was flat at ₹53.84 crore, but the net loss widened from ₹1.46 cr to ₹2.20 cr.
A ₹2.31 crore loss in Q4 erased a marginal nine-month profit.
Auditors issued an unmodified opinion on the financial statements.

Why it matters

Flat revenue paired with a widening loss points to cost pressures or margin erosion at a company already too small to absorb them. The Q4 swing from marginal profit to a deep quarterly loss suggests something broke late in the fiscal year.

What we’re watching

Management commentary on the Q4 deterioration.
Whether the cost pressures are one-off or structural.
Impact on the company's already thin balance sheet.

The full read

Centenial Surgical Suture is a ₹33 crore nano-cap. Its FY26 numbers tell a simple story: revenue didn't move, but the loss grew. Full-year sales held at ₹53.84 crore, yet the net loss widened 51% to ₹2.20 crore from ₹1.46 crore. The damage was concentrated in the final quarter. A ₹2.31 crore Q4 loss erased the marginal profit the company had built through the first nine months. Something shifted in the last three months of the fiscal year, and the result is a company earning no more than it did before, but losing more. The auditors signed off without qualification. The open question is what drove the Q4 deterioration.

Primary source: BSE · NSE

Centenial Surgical Suture posts FY26 results, auditors sign off clean

Tipsheet Editorial — Sat, 30 May 2026 21:28:39 GMT

A routine annual filing for a nano-cap company. The auditors gave an unmodified opinion, but the results carry no strategic surprises.

What’s new

Board approved standalone audited results for Q4 and FY26, ending March 31, 2026.
Auditors issued an unmodified (clean) opinion on the financial statements.
Filing contains no guidance changes, strategic announcements, or material surprises.

Why it matters

This is a compliance filing for a nano-cap. The clean audit opinion is a baseline requirement for continued listing. The absence of new information means the event is already priced in and unlikely to move the stock.

What we’re watching

Any subsequent management commentary or investor presentations.
The stock's liquidity profile given the ₹33 cr market cap.
Whether the next quarter's results show any change in profitability trend.

The full read

Centenial Surgical Suture, a ₹33 crore market-cap company, filed its annual results for the year ended March 31, 2026. The board signed off on the standalone audited accounts, and the auditors gave a clean, unmodified opinion. That's it. There is no new strategy, no guidance update, no surprise. For a nano-cap, this is the baseline. The filing meets its regulatory obligation and adds no new information for investors to act on.

Primary source: BSE · NSE

Centenial Surgical Suture Ltd. (CSURGSU) — Tipsheet

Centenial Surgical Suture posts a ₹2.2 cr annual loss on flat revenue

What’s new

Why it matters

What we’re watching

The full read

Centenial Surgical Suture posts FY26 results, auditors sign off clean

What’s new

Why it matters

What we’re watching

The full read